change control – Page 26

Regulatory query on nitrosamines during supplier audit – CAPA for nitrosamine findings

CAPA Playbook for Managing Nitrosamine Findings in Supplier Audits The emergence of nitrosamines in pharmaceutical manufacturing processes has raised significant regulatory concerns, especially during supplier audits. Actionable insights are critical…

Analytical method sensitivity questioned during submission support – risk mitigation and control strategy

Effectively Managing Concern Over Analytical Method Sensitivity During Submission Support As regulatory scrutiny intensifies, particularly regarding the sensitivity of analytical methods used in pharmaceutical manufacturing, organizations face significant challenges in…

Supplier nitrosamine control weak during ongoing surveillance – FDA/EMA nitrosamine expectations

Strengthening Supplier Nitrosamine Control During Ongoing Surveillance Nitrosamines have emerged as a significant concern in pharmaceutical manufacturing, particularly in relation to raw materials. As organizations strive to ensure compliance with…

Potential nitrosamine source identified during supplier audit – preventing product recall

Addressing Potential Nitrosamine Sources Uncovered in Supplier Audits With increasing scrutiny around nitrosamine impurities, manufacturers face growing pressure to ensure that their raw materials meet strict regulatory guidelines. A recent…

Risk mitigation plan inadequate during submission support – risk mitigation and control strategy

Effective Strategies for Inadequate Risk Mitigation During Submission Support In the evolving landscape of pharmaceutical manufacturing, ensuring rigorous risk management, particularly during submission support phases, is critical. An inadequate risk…

Nitrosamine risk assessment incomplete during ongoing surveillance – risk mitigation and control strategy

Navigating Incomplete Nitrosamine Risk Assessments During Ongoing Surveillance: A Practical Playbook Nitrosamines, particularly in pharmaceutical manufacturing, have emerged as critical components of risk assessment strategies due to regulatory pressures from…

Risk mitigation plan inadequate during regulatory inspection – CAPA for nitrosamine findings

Developing an Effective Risk Mitigation Plan for Nitrosamine Findings During Regulatory Inspections As the pharmaceutical industry navigates increasing scrutiny regarding nitrosamine contamination, professionals across manufacturing and quality sectors must ensure…

Supplier nitrosamine control weak during regulatory inspection – CAPA for nitrosamine findings

Enhancing Supplier Nitrosamine Control for Regulatory Inspections Nitrosamines pose a significant risk in pharmaceutical manufacturing, particularly concerning raw materials. A recent increase in regulatory scrutiny has revealed that many organizations…

Analytical method sensitivity questioned during ongoing surveillance – risk mitigation and control strategy

As pharmaceutical manufacturing operations intensify scrutiny due to evolving regulations and compliance landscapes, analytical method sensitivity has emerged as a critical concern. This issue is particularly acute in the context…

Potential nitrosamine source identified during regulatory inspection – FDA/EMA nitrosamine expectations

Identifying Sources of Nitrosamines During Regulatory Inspections: A Comprehensive Playbook The pharmaceutical industry faces stringent scrutiny regarding the presence of nitrosamines in raw materials. Instances where a potential nitrosamine source…

Regulatory query on nitrosamines during regulatory inspection – CAPA for nitrosamine findings

Playbook for Managing Nitrosamine Regulatory Queries During Inspections Regulatory queries regarding nitrosamines have become increasingly common during inspections by agencies such as the FDA, EMA, and MHRA. These queries often…

Nitrosamine risk assessment incomplete during submission support – inspection-ready justification

Nitrosamine Risk Assessment: Completing the Submission Support Justification Pharmaceutical professionals face increasing scrutiny regarding nitrosamine risks associated with raw materials and excipients. Incomplete risk assessments during submission phases can lead…